: Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008, 14:822–827.PubMedCrossRef 65. Subramanian J, Simon R: Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 102:464–474. 66. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, et al.: Retraction: A genomic strategy to refine prognosis in early-stage PCI-32765 order non-small-cell lung cancer. N Engl J Med 2006;355:570–80. N Engl J Med 364:1176. 67. Pao W, Chmielecki J: Rational,

biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760–774. 68. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, et al.: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983–991.PubMedCrossRef 69. Filipits

M, Pirker R, Dunant A, Lantuejoul S, Schmid K, Huynh A, Haddad V, Andre F, Stahel R, Pignon JP, et al.: Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 2007, 25:2735–2740.PubMedCrossRef 70. Kamal NS, Soria find more JC, Mendiboure J, Planchard D, Olaussen KA, Rousseau V, Popper H, Pirker R, Bertrand P, Dunant A, et al.: MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res 16:1206–1215. 71. Filipits M, Haddad V, Schmid K, Huynh A, Dunant A, Andre F, Brambilla E, Stahel R, Pignon JP, Soria JC, et al.: Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 2007, 13:3892–3898.PubMedCrossRef 72. Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, Saito M, Dunant IMP dehydrogenase A, Pham TC, Petrini I, Lee A, et al.: MicroRNA expression

and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 70:8288–8298. 73. Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu CQ, Livingston R, Johnson DH, et al.: Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007, 25:5240–5247.PubMedCrossRef 74. Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, et al.: Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 28:4417–4424. 75. Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, Lai R, Voloch A, Dumontet C: Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel.